CATX 8-K: Q2 2025 results released; corporate deck updated

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and furnished that press release as Exhibit 99.1 to this Form 8-K. The filing also states the company posted an updated corporate presentation on its website and furnished that presentation as Exhibit 99.2. The 8-K clarifies that the information is "furnished" and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act.

The filing text does not include the actual financial figures or metrics; those details are contained in the referenced exhibits. This disclosure informs investors that quarter-end results and investor materials have been released, while the legal notice about furnishing limits incorporation and Section 18 liability.

Positive

• Press release issued announcing financial results for the quarter ended June 30, 2025 (furnished as Exhibit 99.1).
• Updated corporate presentation posted on the company website and furnished as Exhibit 99.2, providing investors with refreshed materials.

Negative

• Filing does not include in-line financial figures; quantitative results and metrics are only available in the referenced Exhibit 99.1.
• Information furnished, not filed, which the company states limits Section 18 liability and means the 8-K text is procedural rather than substantive.

Insights

Financial Analyst

TL;DR: Company furnished Q2 2025 results and an updated corporate presentation; the 8-K contains no financial figures in-line.

The filing confirms Perspective Therapeutics publicly released results for the quarter ended June 30, 2025 and provided an updated investor deck. From an analyst perspective, the 8-K itself offers procedural confirmation of distribution rather than substantive metrics; readers must review Exhibit 99.1 for earnings, revenues, cash position, or guidance. The statement that the materials are "furnished" (not "filed") limits Section 18 liability and means investors should treat the exhibits as the primary source for any quantitative assessment.

Investor Relations Specialist

TL;DR: Routine investor communication: press release plus updated corporate presentation were posted and furnished as exhibits.

This 8-K reflects standard investor-relations practice: distribute quarter-end results and refresh the corporate presentation, then furnish both as exhibits. The filing explicitly references Exhibit 99.1 (press release) and Exhibit 99.2 (presentation). The notice that the items are "furnished" rather than "filed" is a common disclosure control measure; it does not by itself convey operational or financial performance details.

0000728387false00007283872025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference into this Item 2.02.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

Also on August 13, 2025, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1		Press release issued by Perspective Therapeutics, Inc., dated August 13, 2025.
99.2		Corporate presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	August 13, 2025	By:	/s/ Juan Graham
			Juan Graham Chief Financial Officer

FAQ

What did Perspective Therapeutics (CATX) disclose in this 8-K?

The company announced it issued a press release with financial results for the quarter ended June 30, 2025 (furnished as Exhibit 99.1) and posted an updated corporate presentation (furnished as Exhibit 99.2).

Are the financial numbers included directly in the 8-K for CATX?

No. The 8-K text does not include the financial figures in-line; quantitative details are contained in the referenced Exhibit 99.1 press release.

Where can investors find the detailed results mentioned in the filing?

Investors should review Exhibit 99.1 (the press release) and Exhibit 99.2 (the corporate presentation) furnished with the 8-K for detailed results and slides.

Does the filing indicate any change in legal status of the disclosures?

Yes. The filing explicitly states the materials are "furnished" and therefore are not deemed "filed" for purposes of Section 18 of the Exchange Act.

What period do the reported results cover?

The press release announced financial results for the quarter ended June 30, 2025.